Ultrastaging protocol in sentinel lymph node for apparent early stage ovarian cancer

Lago, V; Montero, Beatriz; López, Susana; Padilla-Iserte, Pablo; Matute, Luis; Marina, Tiermes; Gurrea, Marta; Montoliu, Guillermina; Belló, Pilar

doi:10.1016/j.ygyno.2021.03.001

Cited by 16 publications

(43 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cost-effectiveness analysis was based on estimated costs of pathological ultrastaging at 580 Canadian dollars (≈€392) per patient and standard pathological processing at 375 Canadian dollars (≈€254) per patient. Recently, researchers studying the SLN procedure in ovarian cancer reported a median cost of ultrastaging of €96.8 to €124.5 per patient and €46.1 per SLN [21]. These estimated costs are lower than what we have reported (€275 to €375), mainly due to the low costs for each slide stained with IHC in this Spanish study (€3.5).…”

Section: Discussioncontrasting

confidence: 71%

Value of routine cytokeratin immunohistochemistry in detecting low volume disease in cervical cancer

Baeten

Hoogendam

Jonges

et al. 2022

Gynecologic Oncology

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 71%

Value of routine cytokeratin immunohistochemistry in detecting low volume disease in cervical cancer

Baeten

Hoogendam

Jonges

et al. 2022

Gynecologic Oncology

View full text Add to dashboard Cite

“…The research group of Lago recently published a protocol for ultrastaging of the sentinel node, using section levels deepening every 200 μm -which is more detailed than the section levels every 500 μm used in the current study. The described technique allows an even more reliable detection of micro metastases [28].…”

Section: Discussionmentioning

confidence: 99%

Sentinel lymph node identification in early stage ovarian cancer: is it still possible after prior tumor resection?

et al. 2021

View full text Add to dashboard Cite

Objective Sentinel lymph node (SLN) detection in ovarian cancer is feasible when tracers are injected before the pathological ovary is resected. This study aims to investigate whether the SLN identification is also feasible in patients whose ovarian tumor has already been resected with injection of the tracer into the ovarian ligaments stumps, i.e. in the event that a frozen section confirms malignancy. Methods Patients who underwent laparotomy with frozen section confirming an ovarian malignancy, and those who underwent a second staging laparotomy after prior resection of a malignant ovarian mass, were included. Blue dye and a radioactive isotope were injected in the stumps of the ligamentum ovarium proprium and the ligamentum infundibulo-pelvicum. After an interval of at least 15-min, the sentinel node(s) were identified using either the gamma-probe and / or blue dye. Results A total of 11 patients were included in the study, the sentinel node (SLN) procedure was completed in all 11 patients. At least one SLN was identified in 3 patients, resulting in a rather low detection rate of 27,3%. Conclusion In this study we showed that SLN procedure after (previous) resection of the tumor seems inferior to detect sentinel nodes when compared to injection of the tracer in the ovarian ligaments before tumor resection. Trial registration NCT02540551

show abstract

Section: Introduction To Sentinel Lymph Node Techniquesmentioning

confidence: 99%

“…In one study to determine the role of SLN ultrastaging in early-stage ovarian cancer, 30 patients underwent SLN mapping and pathological ultrastaging with a slice thickness of 200 microns ( 72 ). TC-99m and ICG detection rates were high, reaching 30/30 (100%) and 28/30 (93.3%) ( 72 ). Six people were upgraded after ultrastaging, of which two people found that macrometastases previously failed to be undiscovered, and four patients found implantation in other areas (omentum, fallopian tube, Douglas cavity, etc.)…”

Section: Introduction To Sentinel Lymph Node Techniquesmentioning

confidence: 99%

“…Six people were upgraded after ultrastaging, of which two people found that macrometastases previously failed to be undiscovered, and four patients found implantation in other areas (omentum, fallopian tube, Douglas cavity, etc.) ( 72 ). It was concluded that a uniform ultrastaging protocol was critical for low-volume metastasis detection and for providing repeatable information for future studies ( 72 ).…”

Section: Introduction To Sentinel Lymph Node Techniquesmentioning

confidence: 99%

See 1 more Smart Citation

Sentinel Lymph Node Mapping: Current Applications and Future Perspectives in Gynecology Malignant Tumors

Wang

Shao

et al. 2022

Front. Med.

View full text Add to dashboard Cite

The sentinel lymph nodes (SLNs) is a group of lymph nodes initially involved in the metastatic spread of cancer cells. SLN mapping refers to intraoperative localization and biopsy of SLNs with specific tracers to assess lymph node metastases. It is widely used in a variety of tumor surgeries for its high sensitivity and high negative predictive value. In the evaluation of the status of lymph node metastases in gynecological malignancies, it has received increasingly more attention due to its minor invasiveness, few complications, and high diagnosis rate. The National Comprehensive Cancer Network (NCCN) guidelines provide an excellent introduction to the indications and methods of SLN techniques in vulvar, cervical, and endometrial cancers, but they provide little explanation about some specific issues. In this review, we summarize different dyes and injection methods and discuss the indications of application and the clinical trials of SLN mapping in gynecological malignant tumors, aiming to provide a reference for the rational application of sentinel techniques in gynecology malignant tumors before relevant guidelines are updated.

show abstract

Ultrastaging protocol in sentinel lymph node for apparent early stage ovarian cancer

Cited by 16 publications

References 30 publications

Value of routine cytokeratin immunohistochemistry in detecting low volume disease in cervical cancer

Value of routine cytokeratin immunohistochemistry in detecting low volume disease in cervical cancer

Sentinel lymph node identification in early stage ovarian cancer: is it still possible after prior tumor resection?

Sentinel Lymph Node Mapping: Current Applications and Future Perspectives in Gynecology Malignant Tumors

Contact Info

Product

Resources

About